

## Kymab presents two e-posters at the American Association for Cancer Research Virtual Annual Meeting

**Cambridge, UK; 22 June 2020:** Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that e-posters relating to Kymab's lead immunoncology programs, KY1044 and KY1043, will be presented at the American Association for Cancer Research ("AACR") Virtual Annual Meeting II, being held June 22-24, 2020.

The e-posters are available on the AACR website; the details are as follows:

### **Abstract # 2134**

**Title:** High ICOS/FOXP3 Tregs content in the tumor microenvironment is associated with poorer survival in patients with hepatocellular carcinoma

**Session Type:** Poster Session  
**Session Category:** Tumor Biology  
**E-Poster Number:** 1590

### **Abstract # 2780**

**Title:** KY1043, a novel CD25-directed PD-L1 IL-2 immunocytokine, delivers potent anti-tumor activity in vivo via an expansion of a Tcf1<sup>hi</sup> PD-1<sup>+</sup> CD8<sup>+</sup> T cell population

**Session Type:** Poster Session  
**Session Category:** Therapeutic Antibodies 3  
**E-Poster Number:** 4542

KY1044 is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. KY1044 is designed to exert anti-tumor activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells. A Phase 1/2 clinical trial of KY1044 in patients with advanced solid tumors as a monotherapy and in combination with an anti PD-L1 (atezolizumab) is ongoing.

[Abstract and poster at AACR](#)

[https://vcusa.sparx-ip.net/aacr2020ep/?c=a&searchfor=Sainson&view=1&item=2020AB\\_1590](https://vcusa.sparx-ip.net/aacr2020ep/?c=a&searchfor=Sainson&view=1&item=2020AB_1590)

KY1043 is a human monoclonal antibody that provides targeted immune checkpoint inhibition coupled with dose-dependent anti-tumor activity by combining Kymab's proprietary PD-L1 blocking antibody and a reduced potency, or attenuated, version of the cytokine IL-2 in a single immunocytokine. KY1043 is designed to block immunosuppressive "checkpoint" signals, to allow the immune system to recognize and kill tumors while also localizing IL-2 delivery. These combined activities should increase immune cell recruitment and expansion and anti-tumor activity in the tumor microenvironment.

Abstract and poster at AACR

[https://vcusa.sparx-ip.net/aacr2020ep/?view=1&c=a&searchfor=ky1043&item=2020AB\\_4542](https://vcusa.sparx-ip.net/aacr2020ep/?view=1&c=a&searchfor=ky1043&item=2020AB_4542)

###ENDS###

## NOTES TO EDITORS

### About Kymab

Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab's platforms have been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.

For more information on Kymab please see <http://www.kymab.com>.

### Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

### For further information contact:

#### Kymab

Anne Hyland [anne.hyland@kymab.com](mailto:anne.hyland@kymab.com)  
Brandon Lewis [brandon.lewis@kymab.com](mailto:brandon.lewis@kymab.com)  
+44 (0) 1223 833 301

#### Media UK

Consilium Strategic Communications  
Mary-Jane Elliott / Sukaina Virji / Melissa Gardiner  
[kymab@consilium-comms.com](mailto:kymab@consilium-comms.com)  
Tel: +44 (0) 20 3709 5700